Buagafuran and voriconazole drug interaction study
This study tests how a new medicine (buagafuran) interacts with another medicine (voriconazole) in healthy volunteers. The goal is to understand how the two drugs affect each other in the body, which can help guide safer use in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You must be generally healthy, with no major medical conditions.
- Your weight and body mass index (BMI) must be within a certain range (BMI between 19 and 28, and at least 45 kg for women or 50 kg for men).
- You must have good kidney function (measured by a creatinine clearance test).
- You must be willing to use reliable birth control during the study and for 6 months after.
- You cannot have recently taken certain medications, supplements, or recreational drugs, and you must avoid smoking and alcohol as per the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the body handles a new medicine called buagafuran in people with mild to moderate liver problems compared to people with healthy livers. It helps doctors understand if the dose needs to be adjusted for people with liver issues.
This study checks how the experimental cancer drug vorolanib interacts with other medicines when taken together. It is for healthy people to help find the right dose and safety information before it is tested in patients.
This study is testing whether a common antifungal drug (itraconazole) affects how the body processes a new experimental medicine (HS-10506). The goal is to see if the two drugs can be used together safely.
This study tests how another drug (carbamazepine) affects the amount of an investigational drug (verducatib) in the blood of healthy men. It helps determine if the drugs can be given together safely and how they interact.
This study tests a new drug (clifutinib) in healthy volunteers to see how other common medicines (itraconazole, fluconazole, and efavirenz) affect its levels in the body. The results will help doctors understand how to dose clifutinib in future patients.
This study checks how befotertinib, an experimental cancer drug, interacts with other drugs in healthy people. It helps make sure the drug is safe and works well when taken with other medicines.
Hear when a new Drug Drug Interaction (DDI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.